Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia

Gynecologic Oncology

Volumn 112, Issue 2, 2009, Pages 353-357

  Growdon, Whitfield B ^a,e,f   Wolfberg, Adam J ^b   Goldstein, Donald P ^c,d,e,f   Feltmate, Colleen M ^c,d,e,f   Chinchilla, Manuel E ^c,f   Lieberman, Ellice S ^c,f   Berkowitz, Ross S ^c,d,e,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d New England Trophoblastic Disease Center   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Low risk gestational trophoblastic disease; Persistent GTN; Single agent methotrexate

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL PROTOCOL; CONTROLLED STUDY; CURETTAGE; FEMALE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TROPHOBLASTIC TUMOR;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; HYDATIDIFORM MOLE; METHOTREXATE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREGNANCY; RISK FACTORS;

EID: 58249107812     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.003     Document Type: Article

References (29)

1. Smith H.O. Gestational trophoblastic disease epidemiology and trends. Clin. Obstet. Gynecol. 46 (2003) 541-556
2. Kohorn E.I. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J. Reprod. Med. 47 (2002) 445-450
3. Wolfberg A.J., Feltmate C., Goldstein D.P., Berkowitz R.S., and Lieberman E. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. Obstet. Gynecol. 104 (2004) 551-554
4. Berkowitz R.S., and Goldstein D.P. Chorionic tumors. N. Engl. J. Med. 335 (1996) 1740-1748
5. Goto S., Yamada A., Ishizuka T., and Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol. Oncol. 48 (1993) 165-170
6. Bagshawe K.D., Lawler S.D., Paradinas F.J., Dent J., Brown P., and Boxer G.M. Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 335 (1990) 1074-1076
7. Feltmate C.M., Growdon W.B., Wolfberg A.J., Goldstein D.P., Genest D.R., Chinchilla M.E., et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J. Reprod. Med. 51 (2006) 902-906
8. Hancock B.W., Nazir K., and Everard J.E. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J. Reprod. Med. 51 (2006) 764-766
9. Berkowitz R.S., Goldstein D.P., and Bernstein M.R. Management of nonmetastatic trophoblastic tumors. J. Reprod. Med. 26 (1981) 219-222
10. Soper J.T. Gestational trophoblastic disease. Obstet. Gynecol. 108 (2006) 176-187
11. Lurain J.R., Brewer J.I., Torok E.E., and Halpern B. Gestational trophoblastic disease: treatment results at the brewer trophoblastic disease center. Obstet. Gynecol. 60 (1982) 354-360
12. Kohorn E.I. Single-agent chemotherapy for nonmetastatic gestational trophoblastic neoplasia. Perspectives for the 21st century after three decades of use. J. Reprod. Med. 36 (1991) 49-55
13. McNeish I.A., Strickland S., Holden L., Rustin G.J., Foskett M., Seckl M.J., et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J. Clin. Oncol. 20 (2002) 1838-1844
14. Lurain J.R., and Elfstrand E.P. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am. J. Obstet. Gynecol. 172 (1995) 574-579
15. Garrett A.P., Garner E.O., Goldstein D.P., and Berkowitz R.S. ethotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J. Reprod. Med. 47 (2002) 355-362
16. Soper J.T., Clarke-Pearson D.L., Berchuck A., Rodriguez G., and Hammond C.B. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol. Oncol. 54 (1994) 76-79
17. Berkowitz R.S., Goldstein D.P., and Bernstein M.R. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol. Oncol. 23 (1986) 111-118
18. Berkowitz R.S., and Goldstein D.P. Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms. Obstet. Gynecol. 54 (1979) 725-728
19. Matsui H., Suzuka K., Yamazawa K., Tanaka N., Mitsuhashi A., Seki K., et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol. Oncol. 96 (2005) 616-620
20. Wong L.C., Ngan H.Y., Cheng D.K., and Ng T.Y. Methotrexate infusion in low-risk gestational trophoblastic disease. Am. J. Obstet. Gynecol. 183 (2000) 1579-1582
21. Growdon W.B., Wolfberg A.J., Feltmate C.M., Goldstein D.P., Genest D.R., Chinchilla M.E., et al. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. J. Reprod. Med. 51 (2006) 871-874
22. Wolfberg A.J., Berkowitz R.S., Goldstein D.P., Feltmate C., and Lieberman E. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet. Gynecol. 106 (2005) 548-552
23. van Trommel N.E., Massuger L.F., Schijf C.P., ten Kate-Booij M.J., Sweep F.C., and Thomas C.M. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J. Clin. Oncol. 24 (2006) 52-58
24. Goldstein D.P., Garner E.I., Feltmate C.M., and Berkowitz R.S. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol. Oncol. 95 (2004) 421-422
25. van Trommel N.E., Massuger L.F., Verheijen R.H., Sweep F.C., and Thomas C.M. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol. Oncol. 99 (2005) 6-13
26. Pezeshki M., Hancock B.W., Silcocks P., Everard J.E., Coleman J., Gillespie A.M., et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol. Oncol. 95 (2004) 423-429
27. Osborne R., and Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J. Reprod. Med. 49 (2004) 602-616
28. Hoekstra A.V., Lurain J.R., Rademaker A.W., and Schink J.C. Gestational trophoblastic neoplasia: treatment outcomes. Obstet. Gynecol. 112 (2008) 251-258
29. Osborne R., Filliaci V., Schink J., Mannel R., Provencher D., Alvarez-Secord A., et al. A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. Gynecol. Oncol. 108 (2008) S1